Bellicum adjourns asset-sale special meeting for lack of quorum; issues super-voting share to director

BELLICUM PHARMACEUTICALS, INC

Special meeting to approve sale of assets (CaspaCIDe, iMC, GoCAR-T, Rimiducid) to MD Anderson and dissolution adjourned; only 4,132,740 shares present, short of quorum.
Issued one super-voting share to director Richard A. Fair for $0.01; holder casts votes proportionate to common stock votes at adjourned meeting.
Bylaws amended: quorum now requires majority of voting power present, not majority of outstanding shares.
No financial terms of asset sale disclosed; dissolution plan contingent on stockholder approval.

item 3.02 item 5.03 item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BELLICUM PHARMACEUTICALS, INC: Amended Article III, Section 8 of bylaws to change quorum requirement to a majority of voting power rather than a majority of outstanding shares (effective 2024-01-24).

Change: bylaw amendment
Effective: 2024-01-24

Exact text from the filing

On January 24, 2024, the Board approved the amendment of Article III, Section 8 of the Company’s bylaws to enable the holders of a majority of the voting power of, rather than the majority of, the outstanding shares of stock of the Company entitled to vote at a meeting of stockholders to constitute a quorum for the transaction of business.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BELLICUM PHARMACEUTICALS, INC: Filed Certificate of Designation for Series A Junior Preferred Stock (Super-Voting Share) (effective 2024-01-24).

Change: charter amendment
Effective: 2024-01-24

Exact text from the filing

On January 24, 2024, the Company filed a Certificate of Designation of Series A Junior Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware with respect to the Super-Voting Share.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001539497-24-000104

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.